Dr. Reddy’s continues to expand its portfolio

Dr. Reddy’s proudly announces the launch of Cabazitaxel for Injection, 60 mg/1.5 mL (40 mg/mL) per Single-dose Syringe. Cabazitaxel is a therapy option for mCRPC patients and the therapeutic equivalent generic version of JEVTANA® (cabazitaxel) Injection. “We are excited to expand our injectable portfolio and provide affordable medicines across Canada” says Vinod Ramachandran, Vice President and General Manager, Canada Operations, Dr. Reddy’s Laboratories.  JEVTANA® is a trademark of the Sanofi-aventis. 

Dr. Reddy’s Laboratories Canada, Inc.
5580 Explorer Drive, Suite 204, Mississauga, ON L4W 4Y1

This post is part of CAPhO’s Email Distribution Service on behalf of Dr. Reddy’s and is not an endorsement or recommendation of the product or message content.